Cost Drivers Report 2023
Annual cost growth in Canada’s private drug benefit market is driven by increased utilization and chronic disease drugs, with an increase in claimants post‑pandemic.
Read the full report.
Our resource hub to discover reports, policy papers and other forms of informative content
Annual cost growth in Canada’s private drug benefit market is driven by increased utilization and chronic disease drugs, with an increase in claimants post‑pandemic.
Read the full report.
This study examines and quantifies the value of innovative treatments in Canada to patient lives, the healthcare system and to society. Case studies include: HPV vaccines, Melanoma treatments, treatment for Rheumatoid Arthritis and Hepatitis C.
IMC contracted Reformulary Group to analyze the cost of a private plan prescription drug claim in Canada, and separately in Quebec. This report summarizes that analysis.
Many new therapies coming to the market are not well served by the traditional drug reimbursement approaches currently employed by Canada’s public plans. A growing number of European regulatory authorities have been using novel managed entry agreements (MEA) and innovative access agreements (IAA) to accelerate approval times and improve availability to patients.
The innovative pharmaceutical industry has sponsored over two-thirds of clinical trials initiated in Canada in the last 5 years and contributed over $15 billion to the Canadian economy annually.
A growing number of payers in many countries are looking to managed entry agreements (MEAs) and other innovative access arrangements (IAAs) to allow rapid access to medicines that address significant unmet needs.
Many products coming to market are poorly served by traditional negotiation approaches. This document describes innovative agreements being used in jurisdictions outside Canada. We prepared it to guide discussions with the pCPA Governing Council on the merits of jointly developing an innovative agreements framework.
Our Code of Ethical Practices guides the activities of all our members’ employees as they interact with stakeholders to commercialize prescription medicines (excluding medical devices and over-the-counter products). Adherence to the Code is a condition of membership.
Clinical trials provide Canadian oncology patients with earlier access to new, innovative cancer treatments. But changes pending to the PMPRB will make the Canadian pharmaceutical market less attractive for investment.
The 2021 Cost Drivers report highlights the consistent annual cost growth in the Canadian private drug benefits market and outlines factors that contribute to price increases.
Informative content to keep you up to date on the most pressing issues facing our industry.